clioquinol (nystaform) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Clioquinol is a broad-spectrum antibacterial with antifungal properties, bacteriostatic. It is used as an antifungal and antiprotozoal topical drug OTC product for treatment of human infections. Previousely was used for wide number of intestinal disorders including lambliasis, shigellosis, balantidiral dysentery and some forms of diarrheas. The physiologic effect of clioquinol is by increased histamine release and cell-mediated immunity. It is a member of a family hydroxyquinolines which inhibit certain enzymes related to DNA replication. It is a copper, iron and zink chelating agent. It is an organic molecule with a quinolinic acid as its apparent core which itself is a neurotransmitter. In large doses it possesses neurotoxicity and may induce neurological disease such as subacute myelo-optic neuropathy by creating copper deficiency that leads to zink excess. SMON (Sub-Acute-Myelo-Optical-Neuropathy) - a polio-like disease began as an epidemic in 1959 in Japan was believed to be a Clioquinol caused. Clioquinol is a standardized chemical allergen. It has been resurrected as a potential treatment for Alzheimer's disease since it perturbs metallo-chemistry of amyloid and clioquinol treatment has been shown to be beneficial in a mouse model of Alzheimer's disease.   NCATS

Chemistry

  • SMILES: OC1=C2N=CC=CC2=C(Cl)C=C1I
  • InChIKey: QCDFBFJGMNKBDO-UHFFFAOYSA-N
  • Mol. Mass: 305.5
  • ALogP: 5.41
  • ChEMBL Molecules:
    ufenamate  
    clioquinol  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Combination drugs

( clioquinol (nystaform), nystatin (mycostatin) )

Alternative names

5-chlor-7-jod-8-hydroxy-chinolin | 5-chloro-7-iodo-8-hydroxyquinoline | 5-chloro-7-iodo-8-quinolinol | 5-chloro-7-iodoquinolin-8-ol | 5-chloro-8-hydroxy-7-iodoquinoline | 7-iodo-5-chloro-8-hydroxyquinoline | 7-iodo-5-chloroxine | chloroiodoquin | chloroiodoquine | cleoquinol | clioquinol | clioquinolum | cliquinol | domeform-hc | iodochlorhydroxyquin | iodochlorhydroxyquinoline | iodochlorohydroxyquin | iodochloroxyquinoline | nystaform | oralcer | quin-o-creme | vioform

Organizations (4)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (3)


 

Dermatitis

Eczema

Pruritus Ani

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Eczema (Phase 3)

Hodgkin Disease (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue